These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26310190)

  • 1. Brexpiprazole: First Global Approval.
    Greig SL
    Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
    Citrome L; Stensbøl TB; Maeda K
    Expert Rev Neurother; 2015 Oct; 15(10):1219-29. PubMed ID: 26402059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Stummer L; Markovic M; Maroney M
    Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
    Ekinci A; Ekinci O
    Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
    Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery research and development history of the dopamine D
    Kikuchi T; Maeda K; Suzuki M; Hirose T; Futamura T; McQuade RD
    Neuropsychopharmacol Rep; 2021 Jun; 41(2):134-143. PubMed ID: 33960741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
    McKeage K
    CNS Drugs; 2016 Feb; 30(2):91-9. PubMed ID: 26849053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
    Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole: another multipurpose antipsychotic drug?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Apr; 53(4):23-5. PubMed ID: 25856810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
    Yoshimi N; Futamura T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):356-64. PubMed ID: 25600995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
    Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.